
Aytu BioPharma, Inc.
AYTUNASDAQHealthcareDrug Manufacturers - Specialty & Generic
Regular session
$2.28
−$0.09 · -3.80%
AYTU company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
59
Fair Value
Momentum
34
Weakening
Sentiment
52
Mixed
Risk resilience
47
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteAytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Joshua R. Disbrow
- Listed since
- Sep 25, 2008
- Employees
- 83
Market position
Day range
Current $2.28
52-week range
Current $2.28
- Open
- $2.30
- Previous close
- $2.37
- Volume
- 3.95K
- 0.11× average
- Average volume
- 34.81K
- Average daily volume
- Market cap
- 24.47M USD
- Beta
- 0.26
- Market reference 1
- 50-day average
- $2.2236
- +2.54% above average
- 200-day average
- $2.3737
- -3.95% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 5.67M USD
- P/E (TTM)
- -0.53×
- P/B (TTM)
- 0.68×
- P/S (TTM)
- 0.43×
- EV / EBITDA
- -1.22×
- Earnings yield
- -99.07%
- Free cash flow yield
- -37.73%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 62.50%
- Operating margin
- -26.79%
- Net margin
- -60.17%
- Return on equity
- -71.51%
- Return on assets
- -10.92%
- Return on invested capital
- -10.85%
Financial health
- Debt / equity
- 0.65×
- Current ratio
- 1.26×
Financial statements
Margin trends
Profitability as a percentage of reported revenue.
Income trends
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 66.38M USD | 65.18M USD | 107.4M USD | 96.67M USD | 65.63M USD |
| Cost of goods sold | 20.55M USD | 16.13M USD | 40.77M USD | 46.39M USD | 36.43M USD |
| Gross profit | 45.83M USD | 49.05M USD | 66.63M USD | 50.28M USD | 29.2M USD |
| Research and development | 1.33M USD | 2.77M USD | 4.1M USD | 12.66M USD | 5.62M USD |
| Selling, general, and administrative | 38.29M USD | 42.04M USD | 70.08M USD | 69.88M USD | 55.81M USD |
| Operating expenses | 53.66M USD | 50.65M USD | 83.7M USD | 160.19M USD | 88.07M USD |
| Interest income | — | — | — | 14K USD | — |
| Interest expense | 3.7M USD | 4.79M USD | 4.96M USD | 147.5M USD | — |
| Depreciation and amortization | 5.38M USD | 6.73M USD | 8.82M USD | 10.15M USD | 9.2M USD |
| Operating income | −7.83M USD | −1.59M USD | −17.07M USD | −109.91M USD | −58.87M USD |
| Net income | −13.56M USD | −15.84M USD | −17.05M USD | −108.78M USD | −58.29M USD |
Company facts updated Aug 24, 2026.
AYTU peers
ETFs holding AYTU
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI376.87K0.00%2.3T USD0.03%$377.48—
Vanguard Extended Market ETFVXF205.49K0.00%93.7B USD0.05%$243.82—
Dimensional - US Sustainability Core 1 ETFDFSU11.39K0.00%——$48.23—
Dimensional - US Small Cap ETFDFAS10.43K0.00%——$82.67—
Dimensional - US Core Equity 2 ETFDFAC9.77K0.00%——$45.50—
Dimensional - US Core Equity 1 ETFDCOR5.09K0.00%——$84.405—
Vanguard Morningstar Total Stock Market ETFVTI- Market value
- 376.87K
- Weight
- 0.00%
- AUM
- 2.3T USD
- Expense ratio
- 0.03%
- Price / 1D
- $377.48—
Vanguard Extended Market ETFVXF- Market value
- 205.49K
- Weight
- 0.00%
- AUM
- 93.7B USD
- Expense ratio
- 0.05%
- Price / 1D
- $243.82—
Dimensional - US Sustainability Core 1 ETFDFSU- Market value
- 11.39K
- Weight
- 0.00%
- AUM
- —
- Expense ratio
- —
- Price / 1D
- $48.23—
Dimensional - US Small Cap ETFDFAS- Market value
- 10.43K
- Weight
- 0.00%
- AUM
- —
- Expense ratio
- —
- Price / 1D
- $82.67—
Dimensional - US Core Equity 2 ETFDFAC- Market value
- 9.77K
- Weight
- 0.00%
- AUM
- —
- Expense ratio
- —
- Price / 1D
- $45.50—
Dimensional - US Core Equity 1 ETFDCOR- Market value
- 5.09K
- Weight
- 0.00%
- AUM
- —
- Expense ratio
- —
- Price / 1D
- $84.405—
Continue in GoAI
Research AYTUresearch.disclaimer





